First-hand view: why this choice still trips teams up
I remember the hum of the sequencer in March 2019 at the University of Cape Town; we sent a Visium assay to a local provider and the results came back with uneven coverage across barcoded arrays — and that taught me to be wary. When a biopsy from a Cape Town study produced 1,200 spots with wildly varying transcriptomics signal, which analytic path would actually preserve true cell context and not invent artefact? I write as someone who’s been in spatial biology for over 15 years and who has sat across the bench from lab managers, funders and PI’s deciding on partners. I mention spatial technology companies early because we subcontract for many workflows and I want readers to know where choices begin (and end). Spatial omics service offerings sound similar — but the devil is in sample prep, probe chemistry and imaging pipelines; I’ve seen a perfectly good tissue block ruined by poor permeabilisation and — yes — by rushed QC. Lekker to learn fast, but costly when you don’t.
Here’s a plain complaint: vendors tout high spatial resolution and multiplexed imaging, yet their pipelines often gloss over batch effects or drop low-quality spots rather than reporting them. That practice hides pain — downstream analyses show inflated cell-type co-location and misleading neighbourhood scores. I’ve had teams re-run experiments at considerable expense because initial vendor maps misled a biomarker decision. This is not academic; it is costly and time-consuming. Next, we’ll compare what to watch for when you evaluate providers — practical metrics that actually matter rather than glossy brochures. — Moving on, then.
Forward-looking comparison: what to prioritise when you select a partner
Start with a clear claim: not all spatial technology companies are equal in handling experimental nuance. I’ve audited workflows where laser capture microdissection outperformed array-based capture for fibrotic tissue; conversely, barcoded arrays suit broad tumour mapping. You need a partner who can justify method choice with verifiable QC metrics and raw data access. In practice, that means asking for per-spot read depth distributions, mapping rates, and the vendor’s approach to correcting spatial batch effects. I favour partners who share raw FASTQ files and alignment logs — that transparency saved one Cape Town study from repeating a costly run in June 2021.
What’s Next?
Look ahead: expect integrated pipelines that combine RNA-seq style quantification with multiplexed imaging overlays. I predict more vendors will offer hybrid workflows and on-site training; that reduces transport artefacts and improves reproducibility. When you speak to spatial technology companies, probe their experience with your tissue type, ask for a pilot run, and insist on blinded reproducibility checks. Small aside — insist on a cut of raw metrics; insist. Also, note: turnaround time matters but not at the cost of QC. Short runs can be seductive. Beware.
Three concrete evaluation metrics I use — and you should too
I’ll finish practical: here are three metrics I insist on before committing samples. 1) Per-spot median unique molecular identifier (UMI) counts and their variance — this tells you whether spatial resolution is genuine. 2) Proportion of reads mapped to expected transcripts (mapping rate) and a vendor’s pipeline for handling multi-mapping — poor handling inflates false positives. 3) Reproducibility score from a small pilot (technical replicate correlation; aim for >0.85). Use these to compare quotes and timelines. I genuinely believe a pilot with clear metrics saves months and Rands. Pause — check lab references. Then choose.
Final note: choosing the right spatial omics service is a balance of method fit, transparency and reproducibility. I’ve learned that the cheapest quote rarely wins; the best partner is the one who shares raw data, explains their QC, and stands by results. For practical help and more resources, consider talking to stomics.